A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 5386 participants.

Also called NCT07419828

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 5,386 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07419828
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07419828. Randomized; quadruple masking; primary purpose treatment. Start 2026-03-13 (actual); primary completion 2030-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease
Intervention (Drug)
HRS-1780 tablets
Intervention (Drug)
Placebo
Lead sponsor
Shandong Suncadia Medicine Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07419828
Content hash
7dfed7ba9d1df8ff561c4fb37b510f2e33e1ef57c5268aefe4d4d4c0ba6b7bee